APSR IDI Online KlikPDPI
APSR IDI Online KlikPDPI Halaman Admin Forum Umum Facebook Page Twitter Instagram Youtube
BDP/formoterol MART asthma exacerbation benefit increases with blood eosinophil level
PDPI Jatim, 15 Mar 2021 08:05:59

Extract

A number of studies have evaluated the effectiveness of a “Maintenance And Reliever Therapy” (MART) regimen combining in a single inhaler the rapid-acting, long-acting β2-agonist (LABA) formoterol fumarate (FF) with an inhaled corticosteroid (ICS) in asthma [1–5]. Such a regimen is now established for the treatment of moderate-to-severe asthma in adolescents and adults in many guidelines [6, 7]. Furthermore, rescue short-acting β2-agonists (SABAs) are no longer recommended as sole therapy even for patients with mild asthma, and an ICS/FF combination used as needed is the preferred reliever therapy [6].

MITRA KERJA
VIDEO
Tutorial Aplikasi ISR
Uploaded on May 11, 2015
World Asthma Day 2018
Uploaded on Apr 30, 2018